The report maintains REDUCE on Sudarshan Chemical with TP of INR 1,027, citing uncertain global pigment demand outlook and the stock trading at what it calls contextually high valuations.
Read this note →Sudarshan Chemical Industries Limited
NSE SUDARSCHEM BSE 506655 INE659A01023
0 filings · 0 analysed
1,056.50
+0.45%
over today
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| HDFC Securities | 07 Nov 2026, 06:48 | short | 1,066.60 | 1,027.00 | — | — | open by 2027-11-07 |
| HDFC Securities | 14 Oct 2026, 15:45 | short | 1,144.00 | 1,029.00 | 1,019.60 | 108% | hit |
| HDFC Securities Ltd | 07 Oct 2026, 10:22 | long | 1,226.60 | 1,340.00 | 1,066.60 | -100% | open by 2027-10-07 |
| HDFC Securities | 28 Sep 2026, 12:01 | short | 1,199.60 | 1,028.00 | 1,019.60 | 105% | hit |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report expects APAT to rise 228.8% YoY despite EBITDA margin contraction of 187.3bps QoQ.
Read this note →The note states a short-term 'Buy' on Sudarshan Chemical with a buying range of 1262-1275, add-on-dip at 1225, stop loss at 1199 and target of 1340 within up to 10 days, citing a bullish reversal from the 50 DEMA, a volume jump on intraday charts, a bullish RSI setup on the hourly chart and a higher-top higher-bottom hourly structure.
Read this note →The note maintains a REDUCE rating with the target price raised from INR 911 to INR 1,028 (CMP INR 1,219), saying the recent Clariant Muttenz asset acquisition and VP4 Frankfurt divestment represent disciplined post-Heubach portfolio rationalisation that should aid balance sheet deleveraging, with net debt/EBITDA seen improving from 0.85 in FY27 to 0.20 in FY30 and revenue/EBITDA/APAT CAGR of 6/14/40% over FY27-FY30E, while the stock trades at 54.5/27.8/23.4x FY28/29/30E EPS.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief